Aditxt Inc (NASDAQ:ADTX), a social innovation platform accelerating promising health innovations, announced on Friday that it has acquired Ignite Proteomics, a commercial-stage precision oncology company, to improve therapy selection for patients with metastatic cancer.

Ignite's functional proteomics platform measures protein expression and activity, capturing therapy responses not identified by standard genomic testing.

This acquisition supports Ignite's 2026 programme targeting over 600,000 US patients with limited therapeutic options. Ignite operates a CLIA-certified lab with a Medicare PLA reimbursement pathway of approximately USD2,200 per test, providing a commercial foundation for therapy selection and longitudinal monitoring.

The global cancer profiling market is estimated at USD14bn, with Ignite identifying around USD3bn of serviceable opportunity among patients eligible for antibody drug conjugates and other targeted therapies.

Aditxt acquired Ignite through the issuance of 36,000 Series A-2 Convertible Preferred Stock shares, valued at USD36m.

Ignite will function as a subsidiary within Aditxt's oncology initiatives, integrating its platform into oncology practices and Molecular Tumor Boards to guide treatment decisions based on functional tumour biology.